Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03321747 · ClinicalTrials.gov registry record · Phase 1
Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
A Phase 1 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03321747 is a Phase 1 study that was terminated before completion, run by Indiana University. The registered enrollment target is 13 participants.
The verdict
NCT03321747, a Phase 1 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three fraction SABR is effective for the treatment of early stage non small cell lung carcinoma (NSCLC) of all histologies, it is not safe for many patients. While four and five fraction SABR is safe, recently published data and our institutional data suggests that local control for early stage squamous cell carcinoma of the lung using the current four or five fraction SABR is suboptimal.
Interventions
- RADIATION Stereotactic Ablative Body Radiation (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2020-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03321747
The ClinicalTrials.gov registry entry for NCT03321747 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Body Radiation (SABR) is the first listed.
NCT03321747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03321747 about?
NCT03321747 is a clinical study titled "Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung". The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three fraction SABR is effective for the treatment of early stage non small cell lung carcinoma (NSCLC) of...
What is the current status of trial NCT03321747?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-10-20. Estimated completion is 2020-07-09.
What interventions are being tested in trial NCT03321747?
The interventions under investigation include: Stereotactic Ablative Body Radiation (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03321747?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.